Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Tract Symptoms in Egypt (GERD Q NIS)

AstraZeneca

Status: Completed

Conditions: Patients With Upper Gastro-intestinal Symptoms

Study type: Observational

Funder types: Industry

Identifiers

NCT01635959

NIS-GEG-XXX-2012/1

Details and patient eligibility

About

The purpose of this study is to calculate the prevalence of gastroesophageal reflux disease (GERD) by mean of GERD-Q questionnaire in patients with upper gastrointestinal tract symptoms in Egypt.

Full description

Prevalence of Gastroesophageal reflux disease (GERD) in patients with upper gastrointestinal tract symptoms in Egypt

Enrollment: 3,170 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years and above
• Attending the medical office and reporting symptoms suggestive of upper gastrointestinal tract symptoms such as heartburn/regurgitation, abdominal pain, bloating, belching and nausea/vomiting.

Exclusion criteria

• Participating on a clinical trial during the last 3 months.
• Patients not able to read and/or understand the GERD-Q questionnaire.
• Patients already included in the study in other participating site.
• Patients taking PPIs or H2blockers in the l

Trial design

3,170 participants in 1 patient group

Patients with Gastrointestinal Trackt Symptoms